北海康成生物科技有限公司
制药业
Burlington，Massachusetts 2,886 位关注者
To be a global biopharmaceutical company delivering life-changing therapeutics built upon a foundation in China.
关于我们
北海康成是一家已经进入产品上市运营阶段的新药创制公司。重点开发恶性肿瘤生物靶向创新药和以罕见病为代表的精准治疗等前沿技术领域。 北海康成是一家标志性的新药创制企业，不仅拥有世界级的管理团队和顾问，还具有广泛的国际资源整合能力，卓越的项目执行能力和创新的业务模式。它是生物药“药品上市许可持有人制度（MAH）”的第一批实践公司；是我国首个进入胶质母细胞瘤（GBM）临床II/III期试验的I类创新靶向生物药创新企业，也是本土领域罕见病平台构建的先行者。
- 网站
-
https://www.canbridgepharma.com
北海康成生物科技有限公司的外部链接
- 所属行业
- 制药业
- 规模
- 201-500 人
- 总部
- Burlington，Massachusetts
- 类型
- 上市公司
- 创立
- 2012
- 领域
- Biotechnology、Pharma、Oncology、Rare Disease和Life Sciences
地点
北海康成生物科技有限公司员工
动态
-
We are very happy to share that the Center for Drug Evaluation of the China National Medical Products Administration has granted Priority Review Status to CAN103 for Gaucher Disease. https://lnkd.in/g_utaiZx
-
Our CEO, James Xue, recently had the opportunity to speak with PharmaBoardroom about CANbridge’s journey and our mission to help patients with rare diseases on a global scale. https://lnkd.in/dzwpNa_3
-
It is with great honor and pride that our drug treatment Livmarli is recommended for ALGS treatment by The Chinese Journal of Pediatrics in their publication “Expert Consensus on Diagnosis and Treatment for ALGS Associated Liver Disease”. https://lnkd.in/edaK6T7F